ALT

Altimmune, Inc. is a biotechnology company in the healthcare sector, with a market capitalization of $426.76 million and 59 employees. The company's industry classification is Biotechnology. The financial performance of Altimmune is characterized by significant losses. The net income for the trailing twelve months (TTM) is -$83,915,000, while the EBITDA and free cash flow are also negative at -$90,343,000 and -$37,671,376, respectively. However, the company has a substantial amount of cash on hand, totaling $210.78 million, with relatively low debt of $15.90 million. The profitability metrics are not favorable, with gross margin, operating margin, and profit margin all at 0.0%. The returns on equity and assets are also negative, at -52.6% and -30.9%, respectively. The valuation context for Altimmune is notable due to its low forward P/E ratio of -3.05 and price-to-book ratio of 2.11. Additionally, the price-to-sales ratio is very high at 21338.02, while the EV/EBITDA ratio is also negative at -1.89. The revenue growth for the past year is 0.0%, and there are no earnings growth rates available. Dividend information is not applicable as the dividend yield is N/A.